Tiny Traces, Big Impact: Changing the Paradigm in Breast Cancer Management with MRD Testing
Watch Video
Oncology
Resources related to tests that help detect circulating tumor DNA for molecular residual disease assessment.
-
-
Using Circulating Tumor DNA to Monitor Sarcoma Treatment and Recurrence
Read More
-
ASBrS APP Course
Signatera MRD testing in breast cancer setting
Watch Video
-
ASBrS Symposia
Signatera MRD testing in breast cancer setting
Watch Video
-
GCs in Industry Webinar
Watch Video
-
Signatera Genome Requisition
Please note: only an authorized healthcare provider can submit a test request for Signatera.
Read More
-
Clinical performance of Signatera Genome assay in a cohort of patients with solid tumors
George M, Schwartz G, McHayleh W, et al. ASCO Annual Meeting 2025, Chicago, IL. May 30 - June 3, 2025.
Read More
-
Cell-free DNA: The past, present, and future
Watch Video
-
Optimizing Patient Care in MIBC with MRD Testing, Real-world Clinical Cases
Watch Video
-
Transforming colorectal cancer management with tumor informed ctDNA testing
Listen Now
-
Recio Study 1 Page
Read More
-
Signatera Sample Collection
Watch Video
-
New Data Review Can treating molecular residual disease (MRD) in colorectal cancer improve outcomes
Watch Video
-
A Rare Cancer, A Powerful Tool: What the New Guidelines Mean for Merkel Cell Carcinoma Patients
Read Article
-
How MRD Testing Supports Colorectal Cancer Patients: Jason’s Story and the Importance of Regular Monitoring
Read Article
-
Jason's Patient Testimonial
Watch Video
-
MRD Testing in NSCLC to Personalize Patient Care
Watch Video
-
Unlocking new uses for old drugs
a revolution in precision oncology using evidence-based MRD testing
Watch Video
-
Medicare Expands Coverage of Signatera for Patients with Lung Cancer
Read Article
-
How to Use Natera’s Patient Portal to Manage Your Cancer Care
Read Article
-
Loading More...
